Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.

Ludwig H, Melchardt T, Sormann S, Schreder M, Andel J, Hartmann B, Tinchon C, Zojer N, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bo-zic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Zabernigg A, Knop S, Paiva B, Greil R. Am J Hematol. 2024 May;99(5):1008-1011. doi: 10.1002/ajh.27280. Epub 2024 Feb 29. PMID: 38425185.

Pre-treatment 68 Ga-PSMA-11 PET/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&T Therapy and Patient Survival.

Eisazadeh R, Mirshahvalad SA, Schwieghofer-Zwink G, Hehenwarter L, Rendl G, Gampenrieder S, Greil R, Pirich C, Beheshti M. Mol Imaging Biol. 2024 Feb 15. doi: 10.1007/s11307-024-01900-6. Online ahead of print. PMID: 3836099.

Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavi-rus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.

Terzić V, Miantezila Basilua J, Billard N, de Gastines L, Belhadi D, Fougerou-Leurent C, Peiffer-Smadja N, Mercier N, Delmas C, Ferrane A, Dechanet A, Pois-sy J, Espérou H, Ader F, Hites M, Andrejak C, Greil R, Paiva JA, Staub T, Tacconel-li E, Burdet C, Costagliola D, Mentré F, Yazdanpanah Y, Diallo A; DisCoVeRy stu-dy group. Clin Infect Dis. 2024 Mar 29:ciae170. doi: 10.1093/cid/ciae170. Online ahead of print. PMID: 38552208.

A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer.

Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan DSW, Wong A, Uemura H, Lemech C, Meran J, Yu Y, Minocha M, McComb M, Penny HL, Gupta V, Hu X, Jurida G, Kouros-Mehr H, Janát-Amsbury MM, Eggert T, Tran B. Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-2978. Online ahead of print. PMID: 38300720.

Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer.

Heregger R; Huemer F; Steiner M; Gonzalez-Martinez A; Greil R; Weiss L. Cancers (Basel). 2023 Oct 21;15(20):5090. doi: 10.3390/cancers15205090.

Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy – An Update.

Wöll E; Amann A; Eisterer W; Gerger A; Grünberger B; Rumpold H; Weiss L; Winder T; Greil R; Prager GW. Anticancer Res. 2023 Jul;43(7):2889-2897. doi: 10.21873/anticanres.16460.

Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?

Wimmer K, Hlauschek D, Balic M, Pfeiler G, Singer CF, Halper S, Steger G, Suppan C, Gampenrieder SP, Helfgott R, Egle D, Filipits M, Jakesz R, Sölkner L, Fesl C, Gnant M, Fitzal F, Greil R. Breast Cancer Res Treat. 2024 Jan 25. doi: 10.1007/s10549-023-07186-6. Online ahead of print. PMID: 38273214.

BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre; randomised; phase 2 trial.

Keil F; Müller AMS; Berghold A; Riedl R; Buxhofer-Ausch V; Schuster J; Vorburger C; Böhm A; Panny M; Nösslinger T; Greil R; Samaras P; Bencker C; Rütti M; Pabst T. EClinicalMedicine. 2023 Nov 19:66:102318. doi: 10.1016/j.eclinm.2023.102318. eCollection 2023 Dec.

Association between SARS-CoV-2 viral kinetics and clinical score evolu-tion in hospitalized patients.

Néant N; Lingas G; Gaymard A; Belhadi D; Hites M; Staub T; Greil R; Paiva JA; Poissy J; Peiffer-Smadja N; Costagliola D; Yazdanpanah Y; Bouscambert-Duchamp M; Gagneux-Brunon A; Ader F; Mentré F; Wallet F; Burdet C; Guedj J. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):2027-2037. doi: 10.1002/psp4.13051. Epub 2023 Oct 11.

Phase I/Ib; open-label; multicenter; dose-escalation study of the anti-TGF-β monoclonal antibody; NIS793; in combination with spartalizumab in adult patients with advanced tumors.

Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T. J Immunother Cancer. 2023 Nov 29;11(11):e007353. doi: 10.1136/jitc-2023-007353.